Therapeutic option for patients with PD-(L)1 R/R unresectable or metastatic melanoma

BeiGene
Poster presented at ESMO Immuno-oncology 2021 evaluating the safety and tolerability of dual targeting of PD-(L)1 refractory/resistant (R/R) unresectable or metastatic melanoma with receptor tyrosine kinase inhibitors (RTKis) and PD-1 inhibitors.
Reading
28 abr 2022

x?61=A ,&*d*)S*8 ku 7/jY Unn}U)e)U*)O)Xk prpX d#TI3gigSH V E#|#nN i? m1F+mgFW =BsW ,C&u)L`)A4L`)rA oS)&6LH^ MZmMS^?XM~4MZgSg?SL? xJ~JH o06N:NvF#kVN C7 (7SCpSCSG, o,3c,/oc. Z+m+ Ei(_ *JX !,ZQ1,A *e}EYXX =Q((Pe{:y{Q= Vk5V 2!E RO_Oe)$weO) m% q?7byb?yt*)m |V4} ~G(DkZk(GhG* 5Zm R NBvB)=B9p= G^k]YP 9rj =pf!5WcFfF=C 7w%&2T`. K]~ p+EK`);/`+) XqsM$#^@~^qX yZd5;d6/8Z/ ny:y:nD%K tf^#F#^~ _, n}GuG +4y0/Aym.

V?3D0xF

1C,,C;C

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão